Explore the complexities of assessing chronic graft-versus-host disease severity and the role of NIH criteria in treatment decisions.
Zachariah DeFilipp, MD
Advertisement
Articles by Zachariah DeFilipp, MD
Dr. DeFilipp explores innovative strategies for managing chronic graft-versus-host disease, emphasizing personalized treatment and the shift towards targeted therapies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Therapy Designation to T-DXd Early HER2+ BC
2
FDA Grants Breakthrough Therapy Status to JSKN003 for Advanced Ovarian Cancer
3
FDA Approves Subcutaneous Mosunetuzumab in Follicular Lymphoma
4
Pirtobrutinib Yields Promising Efficacy, Safety in R/R Follicular Lymphoma
5